1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

21 Oct 2020
Admin
News Article

Zydus Cadila Gets Usfda Nod For Overactive Bladder Treatment Drug

Drug Firm Zydus Cadila On Tuesday Said It Has Received Final Approval From The Us Health Regulator To Market Solifenacin Succinate Tablets, Used For Treatment Of Overactive Bladder.The Company Has Received Final Approval From The United States Food And Drug Administration (Usfda) To Market Solifenacin Succinate Tablets, In The Strengths Of 5 Mg And 10 Mg, Zydus Cadila, Part Of The Cadila Healthcare Group, Said In A Regulatory Filing.Solifenacin Succinate Is A Symptomatic Treatment Of Urge Incontinence And/Or Increased Urinary Frequency And Urgency As May Occur In Patients With Overactive Bladder Syndrome.The Company Said The Newly-Approved Medication Will Be Manufactured At The Group'S Formulation Manufacturing Facility At The Special Economic Zone, Ahmedabad.The Group Now Has 309 Approvals And Has So Far Filed Over 390 Abbreviated New Drug Applications Since The Commencement Of The Filing Process In Financial Year 2003-04.Shares Of Cadila Healthcare Were Trading 0.01 Per Cent Higher At Rs 422.55 On Bse.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!